At the news
? BULLISHIMPACT 8/10 8-K filed Aug 6, 2026 at 07:00 ET
Insmed reported Q2 2026 revenue of $425.5M, crushing consensus estimates of $393.4M, driven by a 49% sequential surge in BRINSUPRI sales to $309.2M. The company raised its full-year BRINSUPRI guidance to $1.25B-$1.4B (from 'at least $1B') and boosted its peak revenue estimate for three lead programs to over $14B. The net loss narrowed dramatically to $13.2M ($0.06/share) from $321.7M ($1.70/share) a year ago, signaling a rapid path to profitability.
- Q2 2026 total revenue of $425.5M, up 296% YoY vs $107.4M.
- BRINSUPRI revenue of $309.2M, up 49% sequentially from Q1 2026.
- Full-year 2026 BRINSUPRI guidance raised to $1.25B-$1.40B from 'at least $1B'.
- Peak revenue estimate raised to >$14B combined for BRINSUPRI, TPIP, and ARIKAYCE.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access